- Implied Volatility 41.75% ( +0.18%)
- Historical Volatility 50.39%
- IV Percentile 51%
- IV Rank 39.41%
- IV High 55.30% on 12/12/22
- IV Low 32.93% on 08/30/23
- Put/Call Vol Ratio 2.93
- Today's Volume 11,736
- Volume Avg (30-Day) 7,714
- Put/Call OI Ratio 0.59
- Today's Open Interest 136,784
- Open Int (30-Day) 139,562
Price PerformanceSee More
|Period||Period Low||Period High||Performance|
| || |
+3.55 (+14.17%)since 11/08/23
| || |
-2.51 (-8.07%)since 09/08/23
| || |
-2.66 (-8.51%)since 12/08/22
Most Recent StoriesMore News
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
This gene-editing company could sport a best-in-class platform.
The Ark Invest founder has liked this telehealth stock for several years.
This next-generation gene therapy stock could be a big winner.
This innovator is targeting a huge, rapidly growing market.
Cathie Wood and Bill Gates like this stock, too.
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome.
This stock holds a spot in maverick investor Wood's flagship fund, and analysts agree the cutting-edge diagnostics specialist has plenty of growth potential from current levels.
None of these stocks have outperformed Nvidia so far this year. But the next 12 months could be a different story.
These two high-tech stocks could dramatically outperform the broader market in the years ahead.